Skip to main content

Table 6 Drug survival by biologic drug

From: Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice

Biologic drug Interval % biologics’ survival (95 % CI)
Etanercept 3 years 59 (41–73)
Infliximab 3 years 20 (2–52)
Adalimumab 3 years 54 (33–70)
Rituximab 3 years 45 (10–75)
Abatacept 3 years 63 (33–83)
Tocilizumab 2 years 75 (13–96)